Agios Pharmaceuticals (AGIO) Other Accumulated Expenses (2012 - 2017)

Agios Pharmaceuticals (AGIO) has 6 years of Other Accumulated Expenses data on file, last reported at $1.3 million in Q1 2017.

• Quarterly Other Accumulated Expenses rose 386.84% year-over-year to $1.3 million in Q1 2017, while the trailing twelve-month figure through Mar 2017 was $1.3 million (up 386.84% YoY) and the FY2016 annual result came in at $168000.0, down 87.21% from the prior year.
• Other Accumulated Expenses advanced to $1.3 million in Q1 2017, from $168000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $1.3 million in Q4 2015 to a low of $93000.0 in Q2 2014.
• A 5-year average of $544500.0 and a median of $434000.0 in 2013 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2015 — Other Accumulated Expenses surged 708.6% — and 2016, when it slumped 87.21%.
• Tracing AGIO's Other Accumulated Expenses over 5 years: stood at $140000.0 in 2013, then soared by 215.71% to $442000.0 in 2014, then soared by 197.29% to $1.3 million in 2015, then tumbled by 87.21% to $168000.0 in 2016, then jumped by 670.83% to $1.3 million in 2017.
• The last three Other Accumulated Expenses figures came in at $1.3 million (Q1 2017), $168000.0 (Q4 2016), and $538000.0 (Q3 2016), per Business Quant data.